More troubling is its investment in electronic cigarette maker Juul Labs, which continues to be the subject of close regulatory scrutiny. After Altria wrote off almost two-thirds of its investment in the popular e-cig device maker, the U.S. government still wants to unwind the deal, and despite Juul having submitted its pre-market tobacco product application for review, it's still doubtful it will be approved.